AU2013345494B2 - 1,3-dihydroimidazole-2-thione derivatives for use in the treatment of pulmonary arterial hypertension and lung injury - Google Patents

1,3-dihydroimidazole-2-thione derivatives for use in the treatment of pulmonary arterial hypertension and lung injury Download PDF

Info

Publication number
AU2013345494B2
AU2013345494B2 AU2013345494A AU2013345494A AU2013345494B2 AU 2013345494 B2 AU2013345494 B2 AU 2013345494B2 AU 2013345494 A AU2013345494 A AU 2013345494A AU 2013345494 A AU2013345494 A AU 2013345494A AU 2013345494 B2 AU2013345494 B2 AU 2013345494B2
Authority
AU
Australia
Prior art keywords
thione
dihydroimidazole
compound
aminoethyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013345494A
Other languages
English (en)
Other versions
AU2013345494A1 (en
Inventor
Maria Joao Macedo Da Silva Bonifacio
Patricio Manuel Vieira Araujo Soares Da Silva
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bial Portela and Cia SA
Original Assignee
Bial Portela and Cia SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bial Portela and Cia SA filed Critical Bial Portela and Cia SA
Publication of AU2013345494A1 publication Critical patent/AU2013345494A1/en
Application granted granted Critical
Publication of AU2013345494B2 publication Critical patent/AU2013345494B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2013345494A 2012-11-14 2013-11-14 1,3-dihydroimidazole-2-thione derivatives for use in the treatment of pulmonary arterial hypertension and lung injury Ceased AU2013345494B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261726119P 2012-11-14 2012-11-14
US61/726,119 2012-11-14
PCT/PT2013/000065 WO2014077715A1 (en) 2012-11-14 2013-11-14 1,3-dihydroimidazole-2-thione derivatives for use in the treatment of pulmonary arterial hypertension and lung injury

Publications (2)

Publication Number Publication Date
AU2013345494A1 AU2013345494A1 (en) 2015-05-14
AU2013345494B2 true AU2013345494B2 (en) 2018-03-22

Family

ID=49759506

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013345494A Ceased AU2013345494B2 (en) 2012-11-14 2013-11-14 1,3-dihydroimidazole-2-thione derivatives for use in the treatment of pulmonary arterial hypertension and lung injury

Country Status (23)

Country Link
US (3) US9604970B2 (enExample)
EP (1) EP2919780B1 (enExample)
JP (1) JP6373275B2 (enExample)
KR (1) KR102259938B1 (enExample)
CN (1) CN105025895B (enExample)
AU (1) AU2013345494B2 (enExample)
BR (1) BR112015010969B1 (enExample)
CA (1) CA2890920C (enExample)
CY (1) CY1120953T1 (enExample)
DK (1) DK2919780T3 (enExample)
ES (1) ES2693025T3 (enExample)
HR (1) HRP20181651T1 (enExample)
IN (1) IN2015DN04089A (enExample)
LT (1) LT2919780T (enExample)
MX (1) MX355422B (enExample)
PL (1) PL2919780T3 (enExample)
PT (1) PT2919780T (enExample)
RS (1) RS57874B1 (enExample)
RU (1) RU2718055C2 (enExample)
SI (1) SI2919780T1 (enExample)
SM (1) SMT201800560T1 (enExample)
TR (1) TR201815850T4 (enExample)
WO (1) WO2014077715A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2718055C2 (ru) 2012-11-14 2020-03-30 Биал - Портела и Кa, С.А. Производные 1,3-дигидроимидазол-2-тиона для применения в лечении легочной артериальной гипертензии и повреждения легкого
GB201810395D0 (en) * 2018-06-25 2018-08-08 Bial Portela & Ca Sa Formulations comprising dopamine-beta-hydroxylase inhibitors and methods for their preparation
WO2021005623A1 (en) * 2019-07-08 2021-01-14 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. A vaccine formulation for protection against enterotoxigenic e. coli (etec) and cholera
CN118598820B (zh) * 2024-02-06 2025-07-08 石家庄四药有限公司 一种二苯基三嗪类化合物及其制备方法和应用

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007081232A1 (en) * 2006-01-13 2007-07-19 Bial- Portela & Ca, S.A. Drug combinations
WO2007139413A2 (en) * 2006-05-31 2007-12-06 Bial - Portela & C.A., S.A. Polymorphs of (r) -5- (2-aminoethyl) -1- (6, 8-difluorochroman-3-yl) -1,3- dihydroimidazole-thione hydrochloride
WO2008085074A2 (en) * 2007-01-12 2008-07-17 Bial-Portela & Ca., S.A. 1, 3-dihydroimidazoles for treating cardiovascular disorders
EP1408038B1 (en) * 2002-10-11 2008-08-06 BIAL - Portela & Ca., S.A. Imidazole deriviatives and their use as peripherally-selective inhibitors of dopamine-beta-hydroxylase
WO2008136695A1 (en) * 2007-05-08 2008-11-13 Portela & Ca, S.A. 1, 3-dihydroimidazole- 2 -thione derivatives as inhibitors of dopamine-beta-hydroxylase
WO2009072915A1 (en) * 2007-12-05 2009-06-11 Bial - Portela & Ca., S.A. New salts and crystal forms
WO2009113891A1 (en) * 2008-03-13 2009-09-17 Bial - Portela & Ca., S.A. Catalytic process for asymmetric hydrogenation
WO2009136803A2 (en) * 2008-05-06 2009-11-12 Bial - Portela & Ca., S.A. Process
WO2012087174A2 (en) * 2010-12-22 2012-06-28 BIAL - PORTELA & Cª., S.A. Crystalline forms and processes for their preparation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0623107B2 (ja) * 1990-11-16 1994-03-30 帝人株式会社 プロスタサイクリン類を有効成分とする薬学的組成物
ES2201104T3 (es) * 1994-04-26 2004-03-16 Roche Palo Alto Llc Derivados de benzociclohexilimidazoltiona.
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
CA2412856A1 (en) * 2002-11-27 2004-05-27 Frederic Bodin Pharmaceutical composition for the treatment of pulmonary arterial hypertension
US20100166869A1 (en) * 2007-05-03 2010-07-01 Desai Neil P Methods and compositions for treating pulmonary hypertension
WO2009088530A1 (en) 2008-01-03 2009-07-16 Biomarin Pharmaceutical Inc. Pterin analog for treating bh4 responsive condition
DE102008054205A1 (de) * 2008-10-31 2010-05-06 Bayer Schering Pharma Aktiengesellschaft Verwendung von Helium-Sauerstoff-Gasgemischen zur Behandlung der pulmonalen arteriellen Hypertonie
RU2718055C2 (ru) 2012-11-14 2020-03-30 Биал - Портела и Кa, С.А. Производные 1,3-дигидроимидазол-2-тиона для применения в лечении легочной артериальной гипертензии и повреждения легкого

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1408038B1 (en) * 2002-10-11 2008-08-06 BIAL - Portela & Ca., S.A. Imidazole deriviatives and their use as peripherally-selective inhibitors of dopamine-beta-hydroxylase
WO2007081232A1 (en) * 2006-01-13 2007-07-19 Bial- Portela & Ca, S.A. Drug combinations
WO2007139413A2 (en) * 2006-05-31 2007-12-06 Bial - Portela & C.A., S.A. Polymorphs of (r) -5- (2-aminoethyl) -1- (6, 8-difluorochroman-3-yl) -1,3- dihydroimidazole-thione hydrochloride
WO2008085074A2 (en) * 2007-01-12 2008-07-17 Bial-Portela & Ca., S.A. 1, 3-dihydroimidazoles for treating cardiovascular disorders
WO2008136695A1 (en) * 2007-05-08 2008-11-13 Portela & Ca, S.A. 1, 3-dihydroimidazole- 2 -thione derivatives as inhibitors of dopamine-beta-hydroxylase
WO2009072915A1 (en) * 2007-12-05 2009-06-11 Bial - Portela & Ca., S.A. New salts and crystal forms
WO2009113891A1 (en) * 2008-03-13 2009-09-17 Bial - Portela & Ca., S.A. Catalytic process for asymmetric hydrogenation
WO2009136803A2 (en) * 2008-05-06 2009-11-12 Bial - Portela & Ca., S.A. Process
WO2012087174A2 (en) * 2010-12-22 2012-06-28 BIAL - PORTELA & Cª., S.A. Crystalline forms and processes for their preparation

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CAS Registry Number: 1187481-13-5; STN entry date: 06 Oct 2009; Chemical name: 2H-Imidazole-2-thione, 5-(2-aminoethyl)-1-(6,8-difluoro-3,4-dihydro-2H-1-benzopyran-3-yl)-1,3-dihydro- *
CAS Registry Number: 1195427-89-4; STN entry date: 03 Dec 2009; Chemical name: 2H-Imidazole-2-thione, 5-(aminomethyl)-1-[(3S)-6,8-difluoro-3,4-dihydro-2H-1-benzopyran-3-yl]-1,3-dihydro- *
CAS Registry Number: 1388267-49-9; STN entry date: 09 Aug 2012; Chemical name: 2H-Imidazole-2-thione, 5-(3-aminopropyl)-1-[(3R)-3,4-dihydro-6-hydroxy-2H-1-benzothiopyran-3-yl]-1,3-dihydro- *
CAS Registry Number: 878904-82-6; STN entry date: 02 Apr 2006; Chemical name: 2H-Imidazole-2-thione, 5-(aminomethyl)-1-[(3R)-6-fluoro-3,4-dihydro-2H-1-benzopyran-3-yl]-1,3-dihydro- *
CAS Registry Number: 878904-83-7; STN entry date: 02 Apr 2006; Chemical name: 2H-Imidazole-2-thione, 5-(2-aminoethyl)-1-[(2S)-7-fluoro-1,2,3,4-tetrahydro-2-naphthalenyl]-1,3-dihydro- *

Also Published As

Publication number Publication date
RU2015120164A (ru) 2017-01-10
CN105025895B (zh) 2019-02-26
SI2919780T1 (sl) 2018-12-31
RU2718055C2 (ru) 2020-03-30
US20150299172A1 (en) 2015-10-22
HRP20181651T1 (hr) 2018-12-14
CN105025895A (zh) 2015-11-04
JP2016504286A (ja) 2016-02-12
BR112015010969A2 (pt) 2017-08-22
SMT201800560T1 (it) 2019-01-11
PT2919780T (pt) 2018-11-13
RS57874B1 (sr) 2018-12-31
BR112015010969B1 (pt) 2020-05-26
IN2015DN04089A (enExample) 2015-10-09
US20190241545A1 (en) 2019-08-08
MX355422B (es) 2018-04-18
PL2919780T3 (pl) 2019-01-31
KR20150084022A (ko) 2015-07-21
US10308640B2 (en) 2019-06-04
JP6373275B2 (ja) 2018-08-15
CA2890920A1 (en) 2014-05-22
CA2890920C (en) 2020-12-15
CY1120953T1 (el) 2020-05-29
US9604970B2 (en) 2017-03-28
EP2919780A1 (en) 2015-09-23
DK2919780T3 (en) 2018-11-26
EP2919780B1 (en) 2018-08-01
MX2015005910A (es) 2015-08-10
AU2013345494A1 (en) 2015-05-14
US20170369477A1 (en) 2017-12-28
TR201815850T4 (tr) 2018-11-21
HK1215393A1 (en) 2016-08-26
ES2693025T3 (es) 2018-12-07
LT2919780T (lt) 2018-11-12
KR102259938B1 (ko) 2021-06-03
WO2014077715A1 (en) 2014-05-22

Similar Documents

Publication Publication Date Title
US12144811B2 (en) Combination of a 4-pyrimidinesulfamide derivative with an SGLT-2 inhibitor for the treatment of endothelin related diseases
JP3883205B2 (ja) アンギオテンシン▲ｉｉ▼レセプタ遮断イミダゾールによるアテローム性動脈硬化症の治療
US20190241545A1 (en) 1,3-Dihydroimidazole-2-Thione Derivatives for Use in the Treatment of Pulmonary Arterial Hypertension and Lung Injury
JPH08500103A (ja) アンジオテンシン▲ｉｉ▼受容体拮抗薬としてのイミダゾールカルボン酸のプロドラッグ
AU6291696A (en) Method of treating renal disease using an ace inhibitor and an A II antagonist
CA2318778A1 (en) Method for decreasing qt dispersion or inhibiting the progression of qt dispersion with an angiotensin ii receptor antagonist
EP2157089B1 (en) The therapeutic uses of imidazol-5-carboxylic acid derivatives
AU754852B2 (en) Use of an angiotensin II receptor antagonist for the preparation of drugs to increase the survival rate of renal transplant patients
JP5290190B2 (ja) イミダゾール−５−カルボン酸誘導体の塩、製造方法及びその医薬組成物
HK1215393B (en) 1,3-dihydroimidazole-2-thione derivatives for use in the treatment of pulmonary arterial hypertension and lung injury
US20090281083A1 (en) Combination Product

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired